Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging

Breast Cancer Research and Treatment

Volumn 83, Issue 1, 2004, Pages 67-76

  Martincich, Laura ^a   Montemurro, Filippo ^a   De Rosa, Giovanni ^a   Marra, Vincenzo ^a   Ponzone, Riccardo ^a   Cirillo, Stefano ^a   Gatti, Marco ^a   Biglia, Nicoletta ^a   Sarotto, Ivana ^a   Sismondi, Piero ^a   Regge, Daniele ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Antineoplastic agents combined; Breast neoplasms; Histopathological response; Image processing; Magnetic resonance imaging; Neoadjuvant chemotherapy

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TAXOIDS;

EID: 9144233474     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000010700.11092.f4     Document Type: Article

References (28)

1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998
2. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516, 1988
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr, AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672, 1998
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999
5. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002
6. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417, 1999
7. Vinnicombe SJ, Mac Vicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, Husband JE: Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198: 333-340, 1996
8. Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S: Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20: 553-558, 2000
9. Cocconi G, Di Blasio B, Alberti G, Bisagni G, Botti E, Peracchia G: Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4: 309-313, 1984
10. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91-100, 1996
11. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM: MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magnetic Res Imaging 13: 868-875, 2001
12. Kneeshaw PJ, Turnbull LW, Drew PJ: Current applications and future direction of MR mammography. Br J Cancer 88: 4-10, 2003
13. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T: Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12: 1711-1719, 2002
14. Hawighorst H, Libicher M, Knopp MV, Moehler T, Kauffmann GW, Kaick G: Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magnetic Res Imaging 10: 286-294, 1999
15. Hayes C, Padhani AR, Leach MO: Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15: 154-163, 2002
16. Taylor JS, Reddick WE: Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 41: 91-110, 2000
17. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schonberg SO, Vaupel P, van Kaick G: Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4: 2305-2312, 1998
18. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD: Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magnetic Res Imaging 5: 689-694, 1995
19. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
20. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91: 523-528, 1999
21. Wasser K, Klein SK, Fink C, Junkermann H, Sinn HP, Zuna I, Knopp MV, Delorme S: Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13: 80-87, 2003
22. Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, Lin YC, Tsai CS: Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78: 51-58, 2003
23. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N: MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8: 549-559, 2001
24. Belli P, Costantini M, Romani M, Pastore G: Role of magnetic resonance imaging in inflammatory carcinoma of the breast. Rays 27: 299-305, 2002
25. Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Ludemann HP, Zuna I, Delorme S: Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13: 1213-1223, 2003
26. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magnetic Res Imaging 10: 223-232, 1999
27. Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H, Knopp MV: Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography. Radiologe 37: 470-480, 1997
28. Knopp MV, Weiss E, Sinn HP, Mattem J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G: Pathophysiologic basis of contrast enhancement in breast tumors. J Magnetic Res Imaging 10: 260-266, 1999